TrinetX Study of Hypereosinophilic Syndrome (HES) Without an Identifiable Non-haematological Secondary Cause

AstraZeneca

Status: Completed

Conditions: Hypereosinophilic Syndrome (HES)

Treatments: Other: no intervention

Study type: Observational

Funder types: Industry

Identifiers

NCT06172751

D3254R00004

Details and patient eligibility

About

The purpose of this study is to build the knowledge base on clinical characteristics, clinical management, and treatment outcomes of HES.

Full description

Retrospective database analysis using TriNetX database to describe HES patient characteristics, journey, and disease burden.

Enrollment: 250 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis record of HES (ICD-10-CM D72.11) anytime during 01 October 2020 to 30 June 2023
• At least 12 months of patient insurance record prior to first HES record.

Exclusion criteria

• Any mutation in PDGFRA, PDGFRB or FGFR1 genes (to exclude clonal HES).
• History of BCR-ABL tyrosine kinase inhibitor use: imatinib, dasatinib, nolitinib, bosutinib, ponatinib, asciminib (to exclude clonal HES)
• History of myeloid leukemia, myeloproliferative disorder, myelodysplastic disorder, myelomonocytic leukemia, acute erythroid leukemia, acute megakaryoblastic leukaemia, acute panmyelosis with myelofibrosis, and other specified leukaemias (to exclude reactive HES)
• History of helminthiasis or use of anthelmintic medication (to exclude reactive HES)
• History of autoimmune disease (to exclude reactive HES)
• History of use of specific drugs: antiepileptics, sulfonamides, allopurinol, and immune checkpoint inhibitors (to exclude reactive HES)

Trial design

250 participants in 2 patient groups

anti-IL-5/IL-5R therapy

Description:

Patients initiated anti-IL-5/IL-5R therapy

Treatment:

Other: no intervention

Other: no intervention

other therapies

Description:

Patients initiated other therapies.

Treatment:

Other: no intervention

Other: no intervention